Korea's Shin Poong Seeks EMEA Special Approval For Anti-malarial Drug Pyramax
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Local South Korean drug maker Shin Poong Pharmaceutical submitted a new drug application to the European Medicines Agency for its new artemisinin combination therapy Pyramax (pyronaridine-artesunate) for malaria